Loading company
Vivani Medical, Inc.
VANI · Nasdaq · ·
$1.24-1.6%Sep 29 close
- 1M
- -12.7%
- 6M
- +32.2%
- 1Y
- -12.1%
- 5Y
- -87.9%
VANI · Nasdaq · ·
$1.24-1.6%Sep 29 close
The quarter ending June 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2025 | 3 months toJun 30, 2021 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$6.4M | -$7.1M | +10.83% |
| Profit per share | -$0.07 | -$0.12 | +41.67% |
| Free Cash Flow | -$6.1M | -$6.2M | +0.39% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Vivani Medical, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Vivani Medical, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.